去细胞肺动脉同种瓣行肺动脉瓣置换的前瞻性欧洲多中心研究ESPOIR试验5年结果及ESPOIR注册数据
ESPOIR试验前瞻性纳入121例患者(2014年8月至2016年12月),中位随访5.9年,5年免于取出/再干预率为97.5%。合并注册数据共319例与冷冻保存同种瓣匹配比较,去细胞瓣免于取出率95.5%优于冷冻瓣83.0%(P<0.001)。
要点
- ESPOIR试验5年免于取出/再干预率97.5%(标准差1.5)。
- 合并队列去细胞瓣免于取出率95.5% vs 冷冻瓣83.0%(P<0.001)。
- 10年结构瓣退化去细胞瓣65.5% vs 冷冻瓣47.3%(P=0.11)。
核心结论
- ESPOIR试验5年数据显示去细胞肺动脉同种瓣性能优良且不良事件率低。
- 注册数据至15年与冷冻保存同种瓣匹配比较显示去细胞瓣免于取出率具统计学显著优势。
研究设计与样本
- 前瞻性ESPOIR试验5年分析,纳入2014年8月至2016年12月121例患者(女性59例),中位年龄16.5岁(四分位距11.2-29.8),中位瓣膜直径24 mm。
- ESPOIR试验与注册患者按年龄、心脏缺陷类型和既往手术与冷冻保存同种瓣患者匹配,合并去细胞瓣队列n=319,匹配冷冻瓣患者319例。
主要发现
- 中位随访5.9年(5.4-6.4)期间发生1例死亡(73岁),另有2例围术期死亡,总死亡率为2.5%。
- 637患者年发生1例心内膜炎,发生率为每患者年0.15%。
- 5年时平均峰值压差19.9 mmHg(9.9),平均反流0.9(0.6,0-3级),免于取出/任何再干预率97.5%(1.5)。
- 合并去细胞瓣队列n=319免于取出率95.5%(标准差1.7)优于冷冻瓣83.0%(2.8)(P<0.001)。
- 匹配319例冷冻瓣患者后,10年结构瓣退化去细胞瓣65.5%(标准差4.4)与冷冻瓣47.3%(3.7)比较P=0.11。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Early results from the prospective ESPOIR Trial have indicated excellent results for pulmonary valve replacement using decellularized pulmonary homografts (DPH). METHODS: A 5-year analysis of ESPOIR Trial patients was performed to provide an insight into the midterm DPH performance. ESPOIR Trial and Registry patients were matched with cryopreserved homografts (CH) patients considering patient age, type of heart defect and previous procedures to present the overall experience with DPH. RESULTS: A total of 121 patients (59 female) were prospectively enrolled (8/2014-12/2016), median age 16.5 years (interquartile range 11.2-29.8), and median DPH diameter 24 mm. One death (73 year-old) occurred during a median follow-up of 5.9 years (5.4-6.4), in addition to 2 perioperative deaths resulting in an overall mortality rate of 2.5%. One case of endocarditis in 637 patient-years was noticed, resulting in an incidence of 0.15% per patient-year. At 5 years, the mean peak gradient was 19.9 mmHg (9.9), mean regurgitation 0.9 (0.6, grade 0-3) and freedom from explantation/any reintervention 97.5% (1.5). The combined DPH cohort, n = 319, comprising both Trial and Registry data, showed significantly better freedom from explantation for DPH 95.5% (standard deviation 1.7) than CH 83.0% (2.8) (P < 0.001) and less structural valve degeneration at 10 years when matched to 319 CH patients [DPH 65.5% (standard deviation 4.4) and CH 47.3% (3.7), P = 0.11]. CONCLUSIONS: The 5-year data of the prospective ESPOIR Trial show excellent performance for DPH and low rates of adverse events. ESPOIR Registry data up to 15 years, including a matched comparison with CH, demonstrated statistically significant better freedom from explantation.
引用
- Bobylev D, Horke A, Boethig D, et al. 5-Year results from the prospective European multi-centre study on decellularized homografts for pulmonary valve replacement ESPOIR Trial and ESPOIR Registry data. Eur J Cardiothorac Surg. 2022. PMID: 35425983. doi:10.1093/ejcts/ezac219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。